Timber Pharmaceuticals announced a positive end-of-phase 2 meeting with the FDA about TMB-001 in moderate to severe congenital ichthyosis. Timber also revealed when it plans to start a phase 3 trial.
The FDA approved the topical JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis in September 2021.
Treating these patients can be a challenge, but it can also be ‘as easy as pie’ if you follow these tips.
One of the key differences between diagnosing AD in patients with skin of color compared to White skin is erythema.
AAD vice president challenges dermatologists to advocate for their patients and themselves.
Targeting skin care regimens to the individual patient is most likely to yield compliance to a recommended routine.
Resident billing can have huge financial implications on academic institutions. A poster from the Icahn School of Medicine at Mount Sinai aimed to assess new medical coding lectures and a modified note template at Winter Clinical Dermatology Conference.
More trustworthy sources of information, and data, are needed.
As skin manifestations are commonly the first thing spotted with infectious disease, dermatologists are in a great position to counsel patients about prevention.